Denosumab Biosimilar LY01011 Demonstrates Safety, Immunogeni

Geometric mean ratios of the biosimilar LY01011 and the reference drug for the primary pharmacokinetic parameters were 98.13% and 100.32%, respectively, within the acceptance range between 80 – 125%.

Related Keywords

Helsinki , Eteläuomen Läi , Finland , China , Chinese , , Drug Administration , Shandong Boan Biotechnology Co ,